| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MIC50: 0.25 - 8 μM (Gram-positive pathogens)[1]
Antibacterial agent 125 targets Gram-positive bacteria, including clinically relevant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action involves targeting essential bacterial processes such as cell wall synthesis, protein production, or DNA replication. The compound's ability to inhibit MRSA and prevent resistance development makes it a valuable tool for studying antibacterial resistance mechanisms. |
|---|---|
| ln Vitro |
Antibacterial agent 125 exhibits efficacy against Gram-positive infections that are clinically significant, with MIC50 values ranging from 0.25 to 8 μM[1]. Methicillin-resistant strains of Staphylococcus aureus are inhibited by antibacterial agent 125 without causing cytotoxicity in human cells[1]. features an outstanding safety profile and strong metabolic stability[1]. After ten passages, antibacterial agent 125 does not cause resistance and has a moderate ability to suppress the formation of biofilms[1].
In vitro, Antibacterial agent 125 has potent activity against clinically relevant Gram-positive pathogens with MIC50 values ranging from 0.25 to 8 μM. It exhibits potent inhibition against methicillin-resistant Staphylococcus aureus strains. The compound does not promote resistance even after ten passages and demonstrates moderate capacity to hinder biofilm formation. It shows no cytotoxic effects in human cells. |
| ln Vivo |
In vivo, Antibacterial agent 125 has been studied in animal models of Gram-positive bacterial infections. Its potent activity against MRSA and lack of cytotoxicity suggest potential for therapeutic applications. However, detailed in vivo efficacy, pharmacokinetic, and toxicological data are limited. Further studies are needed to fully characterize its in vivo potential and safety profile.
|
| Enzyme Assay |
For non-cellular assays, Antibacterial agent 125 is evaluated for its antibacterial activity using standard broth microdilution methods. MIC50 values are determined against a panel of Gram-positive bacterial strains. The compound's ability to inhibit biofilm formation is assessed using crystal violet staining or other biofilm quantification methods. Resistance development is evaluated by serial passage experiments. Cytotoxicity to human cells is assessed using standard cell viability assays.
|
| Cell Assay |
In vitro cell culture experiments are performed using Gram-positive bacterial pathogens including Staphylococcus aureus and MRSA strains. Bacteria are treated with Antibacterial agent 125 at concentrations ranging from 0.1 to 50 μM. Endpoints include minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), time-kill kinetics, biofilm formation inhibition, and resistance development. Cytotoxicity to human cells is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse models of Gram-positive bacterial infection, such as skin infection, sepsis, or pneumonia models. Antibacterial agent 125 is administered intravenously, intraperitoneally, or orally. Efficacy is assessed by measuring bacterial load in target organs, survival rates, and clinical signs of infection. Histopathological examination of infected tissues is performed to evaluate treatment response. Pharmacokinetic parameters are determined to guide dosing regimens.
|
| ADME/Pharmacokinetics |
Antibacterial agent 125 has a molecular formula of C15H11ClN2O and a molecular weight of approximately 270.7 g/mol. It is a small molecule with moderate lipophilicity. The compound is typically dissolved in DMSO for in vitro studies and formulated in appropriate vehicles for in vivo administration. Pharmacokinetic properties are not fully characterized, but the compound is expected to have moderate bioavailability based on its chemical properties.
|
| Toxicity/Toxicokinetics |
Antibacterial agent 125 shows no cytotoxic effects in human cells. It does not promote resistance even after ten passages. The compound demonstrates moderate capacity to hinder biofilm formation. Standard laboratory safety precautions should be followed during handling. The compound is for research use only and is not intended for therapeutic applications without further development.
|
| References | |
| Additional Infomation |
Antibacterial agent 125 has potent antibacterial activity against Gram-positive pathogens with MIC50 values of 0.25-8 μM. It inhibits MRSA strains, does not promote resistance, and hinders biofilm formation with no cytotoxicity in human cells. It is used in research on antibacterial activity and drug resistance. The compound is for research use only and is not approved for clinical use.
|
| Molecular Formula |
C15H11CLN2O
|
|---|---|
| Molecular Weight |
270.71364235878
|
| Exact Mass |
270.055
|
| CAS # |
1274611-43-6
|
| PubChem CID |
55084117
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(CC(NC2=CC=C(C#N)C=C2)=O)=CC=CC(Cl)=C1
|
| InChi Key |
QUFHIWLHKLGWNH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11ClN2O/c16-13-3-1-2-12(8-13)9-15(19)18-14-6-4-11(10-17)5-7-14/h1-8H,9H2,(H,18,19)
|
| Chemical Name |
2-(3-chlorophenyl)-N-(4-cyanophenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (923.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6940 mL | 18.4699 mL | 36.9399 mL | |
| 5 mM | 0.7388 mL | 3.6940 mL | 7.3880 mL | |
| 10 mM | 0.3694 mL | 1.8470 mL | 3.6940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
